Comparative Pharmacology
Head-to-head clinical analysis: DROXIA versus TRISENOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIA versus TRISENOX.
DROXIA vs TRISENOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyurea inhibits ribonucleotide reductase, depleting deoxyribonucleotides and inducing fetal hemoglobin (HbF) synthesis.
Arsenic trioxide induces apoptosis in acute promyelocytic leukemia (APL) cells by targeting the PML-RARα fusion protein, leading to its degradation and subsequent differentiation and apoptosis. It also generates reactive oxygen species, disrupts mitochondrial function, and activates caspases.
Hydroxyurea (Drosia) for sickle cell anemia: Oral, starting dose 15 mg/kg once daily; escalate by 5 mg/kg every 12 weeks to maximum 35 mg/kg/day. For essential thrombocythemia: 15-30 mg/kg once daily. For myelodysplastic syndrome: 15-30 mg/kg once daily.
0.15 mg/kg IV daily until bone marrow remission, then 0.15 mg/kg IV 5 days/week for 2 weeks with 2 weeks off for up to 6 cycles.
None Documented
None Documented
3–4 hours in patients with normal renal function; prolonged to 8–12 hours in moderate to severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life for inorganic arsenic is approximately 10-14 hours, with a mean of 12 hours. The methylated metabolites have longer half-lives, contributing to accumulation with repeated dosing. Clinical context: Supports daily dosing schedule with monitoring for toxicity.
Renal: approximately 50% of absorbed dose excreted unchanged in urine. Biliary/fecal: up to 20% excreted in feces as metabolites, with less than 5% as unchanged drug.
Primarily renal excretion of unchanged arsenic (approximately 15-30% of the dose within 24 hours) with the remainder undergoing hepatic methylation to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA), which are excreted renally. Biliary and fecal elimination are minor (<5%).
Category C
Category C
Antineoplastic
Antineoplastic, Arsenic Trioxide